Odyssey Behavioral Healthcare’s 2023 Clinical Outcomes Report Identifies Notable Symptom Improvement From Treatment

BRENTWOOD, TN / ACCESSWIRE / July 16, 2024 / Odyssey Behavioral Healthcare (“Odyssey”), a leading provider of mental health, addiction, and eating disorder treatment services, is proud to announce the release of its 2023 clinical outcomes report earlier this year, identifying significant reduction in client symptomology across its residential treatment programs for mental health, substance use, and eating disorders. New to the 2023 report is the inclusion of Odyssey’s outpatient network, showcasing the impact this expanding continuum of care has in symptom reduction for local communities across the country.

Odyssey Behavioral Healthcare 2023 Clinical Outcomes Report

The need for high-quality treatment continues to increase across the nation. According to recent reports from the National Alliance on Mental Health (NAMI), the National Institute of Mental Health (NIMH), and the National Association of Anorexia Nervosa and Associated Disorders (ANAD), among adults in the U.S.:

  • 1 in 5 experienced a mental illness, with 1 in 20 experiencing a severe mental illness.

  • Over 12 million have thoughts of suicide.

  • Nearly 29 million are currently struggling with an eating disorder.

Odyssey offers a nationwide network of mental health, addiction, and eating disorder treatment centers offering evidence-based programs, including detoxification, inpatient, residential, partial hospitalization, intensive outpatient, and transitional living, to provide each client with the proper care for their specific needs. Clinical and satisfaction data from 5,155 admission/discharge and 3,984 satisfaction surveys were collected and analyzed by Harvard University, McLean Hospital, and Odyssey statisticians using industry-standard and Odyssey-specific tools to ensure outcomes meet the highest measurement criteria.

“Providing superior care to our clients and families is our top priority. Odyssey invests in our clinical outcomes data to continuously improve the care and programs we provide,” said Richard Clark, CEO of Odyssey. “Our industry-leading outcomes and satisfaction scores reflect our dedication in helping each person progress in their recovery. They also highlight our team’s focus on creating effective and helpful experiences at every interaction before admission, during the treatment stay, and post-care through Odyssey’s alumni services.”

Mental health and addiction residential outcomes were measured using BASIS-24, a leading outcomes measure, and highlights from the report include:

Eating disorder residential outcomes were measured using EAT-26, an industry-standard outcomes measure, and BASIS-24. Highlights from the report include:

  • Adolescents experienced a 73% overall reduction in symptoms in 2023, and adults reduced their symptoms by 65%.

  • Over the past three years, clients saw a 62% overall reduction in eating disorder symptoms.

  • In 2023, clients improved their mental health with a 44% reduction in depressive symptoms and a 46% drop in symptoms related to self-harm.

Odyssey measures client and family satisfaction through Joint Commission and CARF compliant surveys delivered at discharge that track their ratings related to various aspects of the program, services, and staff. These surveys provide important feedback used internally to improve programming and each person’s experience before, during, and after treatment. On average, clients and families reported high satisfaction across all areas, with a 4.4 out of 5-star overall rating for residential and outpatient services. This high level of satisfaction is reinforced with 92.4% of more than 800 Google Reviews in 2023 having a 4- or 5-star rating.

To download the report, visit Odyssey’s Clinical Outcomes page.

About Odyssey Behavioral Healthcare

Odyssey, founded in 2015, has a diverse clinical network of services treating adults and adolescents for eating disorders, psychiatric disorders, dual diagnosis, and other addictive disorders. Odyssey provides a continuum of care within our Psychiatric Network and Eating Disorder Network, including inpatient, intensive residential, partial hospitalization, outpatient services, detoxification, and transitional living at over 50 treatment locations and affiliated Odyssey Outpatient Network clinics in 10 states.

Contact Information

Vicki Smith
Chief Marketing Officer, Odyssey Behavioral Healthcare
vickis@odysseybh.com
615-864-8145

SOURCE: Odyssey Behavioral Healthcare

View the original press release on newswire.com.

View the original press release on accesswire.com

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

3 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

4 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

4 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

5 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago